Eldepryl (Selegiline Hydrochloride) - Summary

ELDEPRYL SUMMARY

ELDEPRYL (selegiline hydrochloride) is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.

ELDEPRYL is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.

ELDEPRYL NEWS HIGHLIGHTS

Media Articles Related to Eldepryl (Selegiline)

Parkinson's Disease
Source: MedicineNet levodopa-carbidopa Specialty [2005.12.17]

Transdermal Rotigotine Patch Safe, Effective in Early Idiopathic Parkinson's Disease
Source: Medscape Pharmacotherapy Headlines [2004.06.17]

Additional Pain In Parkinson's Patients Due To Involuntary Muscle Contractions
Source: Body Aches News From Medical News Today [2008.09.09]

Scientists Replicate Diseases In The Lab With New Stem Cell Lines
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.08.08]

more>>

Published Studies Related to Eldepryl (Selegiline)

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2008.03]

A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. [2008]

Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. [2007.11]

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2007.10.31]

Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. [2007.10]

more>>

Clinical Trials Related to Eldepryl (Selegiline)

Evaluation of Adhesion and Dermal Tolerability of EMSAM [Completed]

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly [Completed]

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients [Active, not recruiting]

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease [Recruiting]

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists [Recruiting]

more>>